Inovio Pharmaceuticals Sued for Allegedly Misleading Investors on Drug Approval Status

Inovio Pharmaceuticals Faces Class Action Lawsuits Amid Allegations of Misleading Statements

Inovio Pharmaceuticals, a biotechnology firm specializing in DNA medicines for diseases linked to the human papilloma virus (HPV), finds itself embroiled in class action lawsuits filed in the United States District Court for the Eastern District of Pennsylvania. These legal actions, initiated by prominent law firms including Pomerantz LLP and The Law Offices of Frank R. Cruz, cite potential violations of federal securities laws from October 10, 2023, to December 26, 2025. Central to these allegations is a claim that Inovio's executives provided misleading assurances regarding the Biologics License Application (BLA) for its lead product candidate, INO-3107, intended for treatment of recurrent respiratory papillomatosis (RRP).

The lawsuits claim that Inovio's representatives misled investors into believing that the company would achieve FDA accelerated approval and priority review for INO-3107, with expectations for a rolling submission of the BLA in the second half of 2024. Instead, the complaints suggest that the company was not adequately prepared to submit the application due to undisclosed manufacturing deficiencies in its proprietary CELLECTRA device, which is fundamental to the treatment's efficacy. Such omissions allegedly created an inflated perception of INO-3107's prospects, misleading stakeholders about the biotechnology firm's regulatory advancements and future commercial opportunities.

As the class action lawsuits progress, interested parties are encouraged to inquire about their potential roles as lead plaintiffs, with deadlines set for April 7, 2026. The implications of these legal developments extend beyond immediate financial concerns for investors; they could significantly affect Inovio's reputation and future interactions with regulatory authorities, impacting its broader mission to address pressing healthcare needs through innovative biotech solutions.

Adding to the scrutiny, the lawsuits highlight the essential role that rigorous regulatory compliance plays in the biotechnology sector. Companies like Inovio, focused on transformative medical solutions, must navigate complex regulatory landscapes while communicating their progress. With ongoing litigation poised to unfold, Inovio's stakeholders eagerly await clarity on whether the firm can sustain investor trust and regain momentum in its strategic initiatives.

The situation presents a critical juncture for Inovio as it proactively engages with investors and legal counsel to counter these allegations. Stakeholders may exercise their rights in relation to the actions taken against the company while monitoring the lawsuit's developments for insights into Inovio's capabilities in bringing innovative therapies to market.